Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07171320

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia

Led by Beijing Tiantan Hospital · Updated on 2025-11-17

384

Participants Needed

1

Research Sites

102 weeks

Total Duration

On this page

Sponsors

B

Beijing Tiantan Hospital

Lead Sponsor

J

Jiujiang University Affiliated Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs), such as duloxetine and venlafaxine, have demonstrated efficacy in FM by modulating pain pathways through increased serotonin and norepinephrine availability. Desvenlafaxine, the third SNRI, was found with lower adverse effects compared with duloxetine and venlafaxine. We hypothesize that the combination of pregabalin with desvenlafaxine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.

CONDITIONS

Official Title

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with fibromyalgia according to the 2016 revised criteria
  • Aged 18 years or older
  • Moderate to severe fibromyalgia not relieved by non-drug treatments and no current recommended drug treatments
  • Numeric rating scale score of 4 or higher at baseline
  • Liver enzyme levels less than twice the normal upper limit
  • Kidney function estimated at 30 mL/min/1.73 m2 or higher
  • Able and willing to give informed consent and follow study requirements
Not Eligible

You will not qualify if you...

  • Allergy to pregabalin, desvenlafaxine, or any ingredients
  • History of epilepsy or depression requiring antidepressants
  • Pregnant or breastfeeding
  • Serious uncontrolled diseases such as high blood pressure, diabetes, or heart problems
  • Other acute or chronic pain conditions besides fibromyalgia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Beijing Tiantan Hospital, Beijing, Beijing 100070

Beijing, China

Actively Recruiting

Loading map...

Research Team

F

Fang Luo, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here